Homocysteine Metabolites, Endothelial Dysfunction, and Cardiovascular Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Date 2025 Jan 25

PMID 39859460

Authors

Hieronim Jakubowski

Lukasz Witucki

Affiliations

Soon will be listed here.

Abstract

Atherosclerosis is accompanied by inflammation that underlies cardiovascular disease (CVD) and its vascular manifestations, including acute stroke, myocardial infarction, and peripheral artery disease, the leading causes of morbidity/mortality worldwide. The monolayer of endothelial cells formed on the luminal surface of arteries and veins regulates vascular tone and permeability, which supports vascular homeostasis. Endothelial dysfunction, the first step in the development of atherosclerosis, is caused by mechanical and biochemical factors that disrupt vascular homeostasis and induce inflammation. Together with increased plasma levels of low-density lipoprotein (LDL), diabetes, hypertension, cigarette smoking, infectious microorganisms, and genetic factors, epidemiological studies established that dysregulated metabolism of homocysteine (Hcy) causing hyperhomocysteinemia (HHcy) is associated with CVD. Patients with severe HHcy exhibit severe CVD and die prematurely due to vascular complications. Biochemically, HHcy is characterized by elevated levels of Hcy and related metabolites such as Hcy-thiolactone and N-Hcy-protein, seen in genetic and nutritional deficiencies in Hcy metabolism in humans and animals. The only known source of Hcy in humans is methionine released in the gut from dietary protein. Hcy is generated from S-adenosylhomocysteine (AdoHcy) and metabolized to cystathionine by cystathionine β-synthase (CBS) and to Hcy-thiolactone by methionyl-tRNA synthetase. Hcy-thiolactone, a chemically reactive thioester, modifies protein lysine residues, generating N-homocysteinylated (N-Hcy)-protein. N-Hcy-proteins lose their normal native function and become cytotoxic, autoimmunogenic, proinflammatory, prothrombotic, and proatherogenic. Accumulating evidence, discussed in this review, shows that these Hcy metabolites can promote endothelial dysfunction, CVD, and stroke in humans by inducing pro-atherogenic changes in gene expression, upregulating mTOR signaling, and inhibiting autophagy through epigenetic mechanisms involving specific microRNAs, histone demethylase PHF8, and methylated histone H4K20me1. Clinical studies, also discussed in this review, show that cystathionine and Hcy-thiolactone are associated with myocardial infarction and ischemic stroke by influencing blood clotting. These findings contribute to our understanding of the complex mechanisms underlying endothelial dysfunction, atherosclerosis, CVD, and stroke and identify potential targets for therapeutic intervention.

References

Froese D, Fowler B, Baumgartner M . Vitamin B , folate, and the methionine remethylation cycle-biochemistry, pathways, and regulation. J Inherit Metab Dis. 2019; 42(4):673-685. DOI: 10.1002/jimd.12009. View

Undas A, Ariens R . Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2011; 31(12):e88-99. DOI: 10.1161/ATVBAHA.111.230631. View

Sauls D, Lockhart E, Warren M, Lenkowski A, Wilhelm S, Hoffman M . Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. Biochemistry. 2006; 45(8):2480-7. DOI: 10.1021/bi052076j. View

Loehrer F, Angst C, Brunner F, Haefeli W, Fowler B . Evidence for disturbed S-adenosylmethionine : S-adenosylhomocysteine ratio in patients with end-stage renal failure: a cause for disturbed methylation reactions?. Nephrol Dial Transplant. 1998; 13(3):656-61. DOI: 10.1093/ndt/13.3.656. View

Marczak L, Sikora M, Stobiecki M, Jakubowski H . Analysis of site-specific N-homocysteinylation of human serum albumin in vitro and in vivo using MALDI-ToF and LC-MS/MS mass spectrometry. J Proteomics. 2011; 74(7):967-74. DOI: 10.1016/j.jprot.2011.01.021. View

Gupta S, Kuhnisch J, Mustafa A, Lhotak S, Schlachterman A, Slifker M . Mouse models of cystathionine beta-synthase deficiency reveal significant threshold effects of hyperhomocysteinemia. FASEB J. 2008; 23(3):883-93. PMC: 2653989. DOI: 10.1096/fj.08-120584. View

Lan X, Field M, Stover P . Cell cycle regulation of folate-mediated one-carbon metabolism. Wiley Interdiscip Rev Syst Biol Med. 2018; 10(6):e1426. PMC: 11875019. DOI: 10.1002/wsbm.1426. View

Maclean K, Sikora J, Kozich V, Jiang H, Greiner L, Kraus E . Cystathionine beta-synthase null homocystinuric mice fail to exhibit altered hemostasis or lowering of plasma homocysteine in response to betaine treatment. Mol Genet Metab. 2010; 101(2-3):163-71. PMC: 2954358. DOI: 10.1016/j.ymgme.2010.06.007. View

DE LA HABA G, CANTONI G . The enzymatic synthesis of S-adenosyl-L-homocysteine from adenosine and homocysteine. J Biol Chem. 1959; 234(3):603-8. View

10.

Mens M, Heshmatollah A, Fani L, Ikram M, Ikram M, Ghanbari M . Circulatory MicroRNAs as Potential Biomarkers for Stroke Risk: The Rotterdam Study. Stroke. 2021; 52(3):945-953. DOI: 10.1161/STROKEAHA.120.031543. View

11.

Xiao Y, Zhang Y, Wang M, Li X, Su D, Qiu J . Plasma S-adenosylhomocysteine is associated with the risk of cardiovascular events in patients undergoing coronary angiography: a cohort study. Am J Clin Nutr. 2013; 98(5):1162-9. DOI: 10.3945/ajcn.113.058727. View

12.

Carter A, Cymbalista C, Spector T, Grant P . Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol. 2007; 27(12):2783-9. DOI: 10.1161/ATVBAHA.107.153221. View

13.

Kerins D, Koury M, Capdevila A, Rana S, Wagner C . Plasma S-adenosylhomocysteine is a more sensitive indicator of cardiovascular disease than plasma homocysteine. Am J Clin Nutr. 2001; 74(6):723-9. DOI: 10.1093/ajcn/74.6.723. View

14.

Majtan T, Park I, Carrillo R, Bublil E, Kraus J . Engineering and Characterization of an Enzyme Replacement Therapy for Classical Homocystinuria. Biomacromolecules. 2017; 18(6):1747-1761. DOI: 10.1021/acs.biomac.7b00154. View

15.

Witucki L, Jakubowski H . Homocysteine metabolites inhibit autophagy, elevate amyloid beta, and induce neuropathy by impairing Phf8/H4K20me1-dependent epigenetic regulation of mTOR in cystathionine β-synthase-deficient mice. J Inherit Metab Dis. 2023; 46(6):1114-1130. DOI: 10.1002/jimd.12661. View

16.

Jakubowski H . Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem. 2000; 275(6):3957-62. DOI: 10.1074/jbc.275.6.3957. View

17.

Leopold J . Antioxidants and coronary artery disease: from pathophysiology to preventive therapy. Coron Artery Dis. 2014; 26(2):176-83. PMC: 4315737. DOI: 10.1097/MCA.0000000000000187. View

18.

Chen X, Wang S, Zhou Y, Han Y, Li S, Xu Q . Phf8 histone demethylase deficiency causes cognitive impairments through the mTOR pathway. Nat Commun. 2018; 9(1):114. PMC: 5760733. DOI: 10.1038/s41467-017-02531-y. View

19.

Sikora M, Bretes E, Perla-Kajan J, Utyro O, Borowczyk K, Piechocka J . Homocysteine thiolactone and other sulfur-containing amino acid metabolites are associated with fibrin clot properties and the risk of ischemic stroke. Sci Rep. 2024; 14(1):11222. PMC: 11099160. DOI: 10.1038/s41598-024-60706-2. View

20.

Yu M, Xiong Y, He H, Deng Y . The mechanism of acetylation-mediated fusion of lysosomes with autophagosomes in neurons after ischemic stroke. Life Sci. 2024; 362():123305. DOI: 10.1016/j.lfs.2024.123305. View